A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
NCT ID: NCT00160524
Last Updated: 2018-08-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
596 participants
INTERVENTIONAL
2004-07-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
NCT00160706
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
NCT00152490
Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
NCT00152425
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
NCT00333788
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
NCT00329420
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Certolizumab Pegol
400 mg subcutaneous injection every 4 weeks from Week 2 to Week 362.
Certolizumab Pegol (CDP870)
Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Certolizumab Pegol (CDP870)
Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must be able to understand the information provided to them and give written informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
45102
Birmingham, Alabama, United States
45028
Huntsville, Alabama, United States
45144
Tucson, Arizona, United States
45095
Orange, California, United States
45006
San Diego, California, United States
45131
San Diego, California, United States
45130
Colorado Springs, Colorado, United States
45094
Gainesville, Florida, United States
45029
Jacksonville, Florida, United States
45087
Miami, Florida, United States
45085
Plantation, Florida, United States
45143
Atlanta, Georgia, United States
45064
Savannah, Georgia, United States
45138
Columbus, Indiana, United States
45111
Louisville, Kentucky, United States
45105
Annapolis, Maryland, United States
45033
Chevy Chase, Maryland, United States
45013
Laurel, Maryland, United States
45057
Plymouth, Minnesota, United States
45108
Jefferson City, Missouri, United States
45031
Lincoln, Nebraska, United States
45035
Berlin, New Jersey, United States
45124
Florham Park, New Jersey, United States
45018
New Brunswick, New Jersey, United States
45009
Great Neck, New York, United States
45070
New York, New York, United States
45117
Rochester, New York, United States
45003
Raleigh, North Carolina, United States
45040
Winston-Salem, North Carolina, United States
45081
Cincinnati, Ohio, United States
45091
Cincinnati, Ohio, United States
45054
Dayton, Ohio, United States
45039
Oklahoma City, Oklahoma, United States
45041
Tulsa, Oklahoma, United States
45048
Portland, Oregon, United States
45084
Chattanooga, Tennessee, United States
45113
Germantown, Tennessee, United States
45071
Nashville, Tennessee, United States
45119
Nashville, Tennessee, United States
45022
Houston, Texas, United States
45073
San Antonio, Texas, United States
45020
Salt Lake City, Utah, United States
45139
Salt Lake City, Utah, United States
45052
South Ogden, Utah, United States
45078
Christiansburg, Virginia, United States
45109
Norfolk, Virginia, United States
45135
Tacoma, Washington, United States
11001
Adelaide, , Australia
11016
Ballarat, , Australia
11011
Bankstown, , Australia
11007
Box Hill, , Australia
11013
Frankston, , Australia
11010
Fremantle, , Australia
11015
Garran, , Australia
11017
Herston, , Australia
11014
Lauceston, , Australia
11003
Melbourne, , Australia
11004
Melbourne, , Australia
11005
New Lambton, , Australia
11018
Newtown, , Australia
11012
Parkville, , Australia
46005
Graz, , Austria
46006
Linz, , Austria
46002
Vienna, , Austria
12001
Minsk, , Belarus
12003
Minsk, , Belarus
12002
Vitebsk, , Belarus
13004
Brussels, , Belgium
13001
Ghent, , Belgium
13002
Liège, , Belgium
15001
Sofia, , Bulgaria
15002
Sofia, , Bulgaria
16014
Halifax, , Canada
16021
Ottawa, , Canada
16013
Toronto, , Canada
16001
Vancouver, , Canada
16010
Vancouver, , Canada
18003
Brno, , Czechia
18011
České Budějovice, , Czechia
18006
Hradek Kralove, , Czechia
18009
Mělník, , Czechia
18007
Olomouc, , Czechia
18008
Olomouc, , Czechia
18010
Pardubice, , Czechia
18005
Plzen - Lochotin, , Czechia
18002
Prague, , Czechia
18004
Prague, , Czechia
18012
Prague, , Czechia
19004
Aalborg, , Denmark
19002
Aarhus, , Denmark
19008
Copenhagen, , Denmark
19009
Copenhagen, , Denmark
19001
Glostrup Municipality, , Denmark
19010
Herlev, , Denmark
19007
Hvidovre, , Denmark
19005
Odense C, , Denmark
20001
Tallinn, , Estonia
20002
Tartu, , Estonia
48001
Tbilisi, , Georgia
22002
Berlin, , Germany
22006
Berlin, , Germany
22009
Berlin, , Germany
22021
Cologne, , Germany
22026
Dresden, , Germany
22013
Göttingen, , Germany
22017
Hanover, , Germany
22015
Kiel, , Germany
22024
Leipzig, , Germany
22003
Magdeburg, , Germany
22001
Minden, , Germany
22008
Münster, , Germany
22005
Wilhelmshaven, , Germany
23002
Shatin, , Hong Kong
24002
Budapest, , Hungary
24012
Budapest, , Hungary
24015
Budapest, , Hungary
24001
Debrecen, , Hungary
24014
Dunaújváros, , Hungary
24010
Győr, , Hungary
24005
Gyula, , Hungary
24009
Pécs, , Hungary
24008
Szeged, , Hungary
24011
Szekszárd, , Hungary
24007
Veszprém, , Hungary
26004
Beersheba, , Israel
26007
Haifa, , Israel
26006
Jerusalem, , Israel
27002
Bologna, , Italy
27001
Milan, , Italy
27004
Palermo, , Italy
27006
Roma, , Italy
27007
Roma, , Italy
28001
Riga, , Latvia
28003
Riga, , Latvia
29001
Kaunas, , Lithuania
31002
Auckland, , New Zealand
31001
Christchurch, , New Zealand
31005
Hamilton, , New Zealand
31003
Tauranga, , New Zealand
31004
Tauranga, , New Zealand
32009
Hamar, , Norway
32001
Haugesund, , Norway
32005
Oslo, , Norway
32008
Oslo, , Norway
32004
Tromsø, , Norway
33022
Bialystok, , Poland
33004
Bydgoszcz, , Poland
33002
Krakow, , Poland
33010
Krakow, , Poland
33011
Lodz, , Poland
33012
Lodz, , Poland
33019
Lublin, , Poland
33020
Opole, , Poland
33003
Sopot, , Poland
33013
Szczecin, , Poland
33001
Warsaw, , Poland
33007
Warsaw, , Poland
33009
Warsaw, , Poland
33016
Warsaw, , Poland
33006
Wroclaw, , Poland
33021
Wroclaw, , Poland
34017
Lipetsk, , Russia
34006
Moscow, , Russia
34015
Moscow, , Russia
34016
Nizhny Novgorod, , Russia
34001
Saint Petersburg, , Russia
34005
Saint Petersburg, , Russia
34007
Saint Petersburg, , Russia
34013
Saint Petersburg, , Russia
34008
Volgograd, , Russia
35001
Belgrade, , Serbia
35002
Belgrade, , Serbia
35004
Belgrade, , Serbia
35005
Belgrade, , Serbia
35003
Niš, , Serbia
36001
Singapore, , Singapore
36002
Singapore, , Singapore
38001
Celje, , Slovenia
38003
Ljubljana, , Slovenia
38004
Novo Mesto, , Slovenia
39003
Cape Town, , South Africa
39016
Cape Town, , South Africa
39017
Cape Town, , South Africa
39011
Durban, , South Africa
39012
Goodwood, , South Africa
39002
Johannesburg, , South Africa
39007
Johannesburg, , South Africa
39010
Johannesburg, , South Africa
39013
Johannesburg, , South Africa
39008
Midrand, , South Africa
39004
Port Elizabeth, , South Africa
39006
Pretoria, , South Africa
39014
Pretoria, , South Africa
39019
Pretoria, , South Africa
40009
Barcelona, , Spain
41001
Stockholm, , Sweden
41004
Stockholm, , Sweden
41002
Umeå, , Sweden
43005
Crimean Autonomy, , Ukraine
43002
Dniepropetrovsk, , Ukraine
43008
Dniepropetrovsk, , Ukraine
43004
Donetsk, , Ukraine
43001
Kharkiv, , Ukraine
43007
Kiev, , Ukraine
43003
Lviv, , Ukraine
43006
Odesa, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lichtenstein GR, Thomsen OO, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ; Precise 3 Study Investigators. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul;8(7):600-9. doi: 10.1016/j.cgh.2010.01.014. Epub 2010 Feb 1.
Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Inflamm Bowel Dis. 2017 Jul;23(7):1047-1056. doi: 10.1097/MIB.0000000000001100.
Melmed GY, McGovern D, Schreiber S, Kosutic G, Spearman M, Coarse J, Sandborn WJ. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol. Curr Med Res Opin. 2016 Dec;32(12):1937-1941. doi: 10.1080/03007995.2016.1221802. Epub 2016 Aug 22.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-002622-60
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
C87033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.